Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...

An artificial intelligence (AI)-enabled hand sensor delivering closed-loop haptic feedback appeared to be an effective ...

If you’ve been battling with dry, itchy skin, you might be dealing with atopic dermatitis, also known as atopic eczema. It’s ...

Scratching isn’t just a bad habit — it’s an immune defense mechanism. While it fuels inflammation, it also helps fight ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Your indoor versus outdoor environment could have an even bigger impact on your eczema symptoms than you realize.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

This research describes a groundbreaking digital health technology designed to measure and reduce nighttime scratching in people with mild atopic dermatitis. Itch, also called pruritus ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...